問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

何宜承

Recruiting

List

27Cases

2024-01-01 - 2027-12-31

Phase III

Active
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

  • Condition/Disease

    Moderate to Severe Plaque Psoriasis

  • Test Drug

    N/A

Participate Sites
7Sites

Recruiting7Sites

2020-12-31 - 2023-12-31

Phase III

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Experienced Subjects with Active Psoriatic Arthritis I (INSPIRE 1)

  • Condition/Disease

    Active Psoriatic Arthritis

  • Test Drug

    Tildrakizumab

Participate Sites
9Sites

Recruiting9Sites

2017-01-01 - 2019-11-30

Phase II

A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects with Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations

  • Condition/Disease

    1. Systemic Lupus Erythematosus and Active Skin Manifestations2. Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations

  • Test Drug

    BIIB059

Participate Sites
4Sites

Recruiting4Sites

方耀凡
Linkou Chang Gung Medical Foundation

Division of Rheumatology

2023-07-31 - 2026-05-27

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2019-04-01 - 2022-06-20

Phase III

A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.

  • Condition/Disease

    Atopic Dermatitis

  • Test Drug

    Lebrikizumab

Participate Sites
7Sites

Recruiting7Sites

2019-10-01 - 2021-12-31

Phase III

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of BMS-986165 in Subjects With Moderate-to-Severe Plaque Psoriasis

  • Condition/Disease

    Moderate-to-Severe Plaque Psoriasis

  • Test Drug

    BMS-986165

Participate Sites
4Sites

Recruiting4Sites

2021-04-01 - 2024-03-01

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB